A Phase 2, Double-blind, Randomized, Placebo-controlled Study to Investigate the Safety, Tolerability, and Efficacy of JBT-101 in Subjects With Dermatomyositis

Trial Profile

A Phase 2, Double-blind, Randomized, Placebo-controlled Study to Investigate the Safety, Tolerability, and Efficacy of JBT-101 in Subjects With Dermatomyositis

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Nov 2017

At a glance

  • Drugs Ajulemic acid (Primary)
  • Indications Dermatomyositis
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Corbus Pharmaceuticals
  • Most Recent Events

    • 08 Nov 2017 Results comparing the safety the efficacy in trial patients (n=22) and general dermatomyositis population at the same clinic (n=221) presented at the 81st American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting
    • 08 Nov 2017 According to a Corbus Pharmaceuticals media release, Detailed Phase 2 results of safety and primary and secondary efficacy assessments were presented in a late-breaking poster presentation at the ACR Annual Meeting.
    • 19 Oct 2017 Results published in a Corbus Pharmaceuticals Media Release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top